-
ITCI Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Intra-Cellular Therapies (ITCI)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm |
Cash burn (monthly) | 52.45 mm | (no burn) | 9.73 mm | 9.73 mm | 4.36 mm | 6.10 mm |
Cash used (since last report) | 198.12 mm | n/a | 36.76 mm | 36.74 mm | 16.47 mm | 23.03 mm |
Cash remaining | 110.58 mm | n/a | 271.94 mm | 271.96 mm | 292.23 mm | 285.67 mm |
Runway (months of cash) | 2.1 | n/a | 27.9 | 28.0 | 67.0 | 46.8 |
13F holders | Current |
---|---|
Total holders | 383 |
Opened positions | 72 |
Closed positions | 38 |
Increased positions | 130 |
Reduced positions | 133 |
13F shares | Current |
---|---|
Total value | 7.78 tn |
Total shares | 100.23 mm |
Total puts | 104.80 k |
Total calls | 283.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 11.08 mm | $925.10 bn |
Vanguard | 9.72 mm | $811.93 bn |
BlackRock | 6.11 mm | $510.53 bn |
JPM JPMorgan Chase & Co. | 5.13 mm | $428.13 bn |
BBBOF BB Biotech | 3.54 mm | $112.52 mm |
Wasatch Advisors | 3.25 mm | $271.34 bn |
Norges Bank | 3.21 mm | $268.35 bn |
IVZ Invesco | 3.08 mm | $257.01 bn |
Avoro Capital Advisors | 3.05 mm | $254.74 bn |
BLVGF Bellevue | 2.44 mm | $203.81 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 25 | Suresh K. Durgam | Common Stock | Sale back to company | Dispose D | No | No | 132 | 42,913 | 5.66 mm | 0 |
2 Apr 25 | Suresh K. Durgam | Performance Stock Units Common Stock | Sale back to company | Dispose D | No | No | 0 | 8,742 | 0.00 | 0 |
2 Apr 25 | Suresh K. Durgam | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 8,742 | 0.00 | 8,742 |
2 Apr 25 | Suresh K. Durgam | Performance Stock Units Common Stock | Sale back to company | Dispose D | No | No | 0 | 13,134 | 0.00 | 0 |
2 Apr 25 | Suresh K. Durgam | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 13,134 | 0.00 | 13,134 |
2 Apr 25 | Suresh K. Durgam | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 24,621 | 0.00 | 0 |
2 Apr 25 | Suresh K. Durgam | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 17,485 | 0.00 | 0 |
2 Apr 25 | Suresh K. Durgam | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 13,133 | 0.00 | 0 |
2 Apr 25 | Suresh K. Durgam | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 56.73 | 17,916 | 1.02 mm | 0 |
2 Apr 25 | Suresh K. Durgam | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 36.89 | 18,714 | 690.36 k | 0 |